Last reviewed · How we verify
Azilsartan medoxomil and olmesartan
Azilsartan medoxomil and olmesartan is a Angiotensin II receptor blocker (ARB) Small molecule drug developed by Takeda. It is currently in Phase 3 development for Hypertension (investigational combination therapy). Also known as: TAK-491, Edarbi.
This combination of two angiotensin II receptor blockers (ARBs) blocks the angiotensin II type 1 receptor to reduce blood pressure and provide cardiovascular protection.
This combination of two angiotensin II receptor blockers (ARBs) blocks the angiotensin II type 1 receptor to reduce blood pressure and provide cardiovascular protection. Used for Hypertension (investigational combination therapy).
At a glance
| Generic name | Azilsartan medoxomil and olmesartan |
|---|---|
| Also known as | TAK-491, Edarbi |
| Sponsor | Takeda |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Azilsartan medoxomil is a prodrug that is hydrolyzed to azilsartan, an ARB with high affinity and selectivity for the AT1 receptor. Olmesartan is also an ARB targeting the same receptor. The combination aims to provide enhanced or complementary antihypertensive and renoprotective effects through dual ARB therapy, though such combinations are not standard clinical practice and this appears to be an investigational approach.
Approved indications
- Hypertension (investigational combination therapy)
Common side effects
- Hyperkalemia
- Dizziness
- Fatigue
- Hypotension
- Renal impairment
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
- Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? (PHASE3)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty
- Azilsartan in Chinese Patients With Mild and Moderate Hypertension (PHASE3)
- Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics (PHASE4)
- Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azilsartan medoxomil and olmesartan CI brief — competitive landscape report
- Azilsartan medoxomil and olmesartan updates RSS · CI watch RSS
- Takeda portfolio CI
Frequently asked questions about Azilsartan medoxomil and olmesartan
What is Azilsartan medoxomil and olmesartan?
How does Azilsartan medoxomil and olmesartan work?
What is Azilsartan medoxomil and olmesartan used for?
Who makes Azilsartan medoxomil and olmesartan?
Is Azilsartan medoxomil and olmesartan also known as anything else?
What drug class is Azilsartan medoxomil and olmesartan in?
What development phase is Azilsartan medoxomil and olmesartan in?
What are the side effects of Azilsartan medoxomil and olmesartan?
What does Azilsartan medoxomil and olmesartan target?
Related
- Drug class: All Angiotensin II receptor blocker (ARB) drugs
- Target: All drugs targeting AT1 receptor (Angiotensin II type 1 receptor)
- Manufacturer: Takeda — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension (investigational combination therapy)
- Also known as: TAK-491, Edarbi
- Compare: Azilsartan medoxomil and olmesartan vs similar drugs
- Pricing: Azilsartan medoxomil and olmesartan cost, discount & access